This randomised double-blinded cross-over study demonstrated for the first time that the oral SIRT1 activator, SRT2104, may improve arterial compliance in otherwise healthy cigarette smokers and in people with type 2 diabetes, without affecting resting measures of blood pressure. This evidence concerns the gene SIRT1 and type 2 diabetes mellitus.